Clinical Study
Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation
Table 4
Rates of pseudoprogression reported in the literature in patients treated with radiotherapy and temozolomide.
| Author | Year | Number of patients | Response criteria | Period of early-response assessment (months) | Number with ePD | psPD (% of ePD) | Overall rate of psPD |
| Chamberlain et al. [20] | 2007 | 51 | Not specified | 6 | 26 | 7/15 (47%) | 7/40 (18%) | Brandes et al. [13] | 2008 | 103 | Macdonald | 1 | 50 | 32/50 (64%) | 32/103 (31%) | Taal et al. [19] | 2008 | 68 | Macdonald | 1 | 31 | 15/31 (48%) | 15/68 (22%) | Chaskis et al. [21] | 2009 | 54 | Gd-MRI + clinical | 6 | 25 | 3/12 (12%) | 3/54 (6%) | Clarke and Chang [22] | 2009 | 85 | Macdonald | 0.5–1 | 35 | 10/27 (37%) | 10/77 (13%) | Fabi et al. [23] | 2009 | 12 | Macdonald | 2 | 4 | 2/4 (50%) | 2/12 (17%) | Peca et al. [24] | 2009 | 50 | Gd-MRI + MR Spectroscopy | 6 | 15 | 4/15 (27%) | 4/50 (8%) | Roldan et al. [8] | 2009 | 43 | Macdonald | 1–1.5 | 25 | 10/20 (50%) | 10/38 (26%) | Gerstner et al. [25] | 2009 | 45 | Macdonald | 0.5–1 | 24 | 13/24 (54%) | 13/45 (29%) | Sanghera et al. [5] | 2010 | 104 | RECIST | 2 | 27 | 7/22 (32%) | 7/99 (7%) | Tsien et al. [10] | 2010 | 27 | Macdonald | 3 | 14 | 6/14 (43%) | 6/27 (22%) | Yaman et al. [26] | 2010 | 67 | Gd-MRI + T2/FLAIR | 6 | 17 | 4/17 (24%) | 4/67 (6%) | Gunjur et al. [27] | 2011 | 68 | Macdonald | 1 | 41 | 14/41 (34%) | 14/68 (21%) | Kang et al. [12] | 2011 | 35 | Macdonald | 1 | 18 | 8/18 (44%) | 8/35 (23%) | Kong et al. [17] | 2011 | 90 | Macdonald + rCBV | 2 | 59 | 26/59 (44%) | 26/90 (29%) | Young et al. [28] | 2011 | 321 | Macdonald | 0.5–1 | 205 | 30/93 (32%) | Not specified | Park et al. [29] | 2011 | 48 | Macdonald | 1 | 25 | 11/25 (44%) | 11/48 (23%) | Topkan et al. [30] | 2012 | 63 | Macdonald | 6 | 28 | 12/28 (43%) | 12/63 (19%) | Pouleau et al. [14] | 2012 | 63 | Gd-MRI + edema | 2 | 33 | 7/33 (21%) | 7/63 (11%) | Present study | 2013 | 70 | RANO Macdonald | 3 | 15 42 | 2/15 (13%) 10/42 (24%) | 2/70 (3%) 10/70 (14%) |
|
|
ePD: early progressive disease; tPD: true progressive disease; psPD: pseudoprogression; Gd-MRI: gadolinium enhanced-MRI.
|